PTPN11 and non-small cell lung carcinoma: In ALK rearrangement NSCLC, SHP2 inhibitors combined with ALK inhibitors showed aggressive anti-tumor effect than a single drug in vivo and in vitro, and reversed the resistance of ALK inhibitors [65].